About Our Lab
Antiphospholipid syndrome (APS) is an unpredictable, chronic autoimmune disease that can cause dangerous clots to form in the body's blood vessels. An estimated 200,000 people in the United States have this condition that leads to serious and sometimes life-threatening complications including stroke, heart attack, and pregnancy-related problems such as miscarriage or premature birth.
Our team, along with many collaborators across Michigan Medicine, are working to advance the understanding of the disease process and identify new, sophisticated approaches to the treatment of APS that are both personalized and proactive. We are also taking what we learn about blood clotting in APS and applying that knowledge to other diseases including lupus, diabetes, and COVID-19.
Dr. Jason Knight and Dr. Yu (Ray) Zuo give a virtual tour of their lab and discuss their research work on APS and COVID-19.
The patients in our APS clinic help to accelerate our research and are our most important partners in our fight against APS. Patients seen in our clinic are given the opportunity to be a part of our ANSWERS study, a prospective cohort study in which we regularly sample blood in pursuit of deep molecular phenotyping. Blood samples are taken to our lab, where we study the process of how antiphospholipid antibodies accelerate blood clotting. We believe this study will eventually allow us to treat patients before their first blood clot even happens.
Please visit the Antiphospholipid Syndrome Program section on UofMHealth.org to learn about APS and how to make an appointment at our clinic.
Join Our Email List
If you are interested in receiving updates on our patient care and research efforts, please join our APS Program email list.
PROTHROMBOTIC AUTOANTIBODIES IN SERUM FROM PATIENTS HOSPITALIZED WITH COVID-19
Prothrombotic Autoantibodies in Serum from Patients Hospitalized with COVID-19, published in Science Translational Medicine on November 2, is featured in over 95 news outlets.
To make a gift to support our COVID-19 research, please visit: COVID-19 Research Fund (Knight Lab).
To make a gift to support our APS research, please visit: APS Gift Fund (Knight Lab).
- Novel Autoantibody Adds Fuel to COVID-19 “Firestorm” of Inflammation, Blood Clots, Michigan Medicine Health Lab, July 19, 2021
- Missing Link: Lingering Questions at the Intersection of COVID-19 and Autoimmunity, Healio Rheumatology, May 20, 2021
- Research by the Knight Lab that found that 52% of 172 people hospitalized with COVID-19 had autoimmune antiphospholipid antibodies is featured in JAMA Network and Nature.
- Ginger Counters Certain Autoimmune Diseases in Mice, Michigan Medicine Health Lab, January 6, 2021
- ‘Spider-Man’ Immune Response May Promote Severe COVID-19, Scientific American, April 28, 2020
- Autoantibodies Stabilize Neutrophil Extracellular Traps in COVID-19, JCI Insight, June 24, 2021
- Endoplasmic Reticulum Stress Sensor IRE1α Propels Neutrophil Hyperactivity in Lupus, The Journal of Clinical Investigation, February 9, 2021
- Anti–Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation
in Antiphospholipid Syndrome, Arthritis & Rheumatology, July 30, 2020
- Neutrophil Extracellular Traps in COVID, JCI Insight, April 24, 2020
- Adenosine Receptor Agonism Protects Against NETosis and Thrombosis in Antiphospholipid
Syndrome, Nature Communications, April 23, 2019